Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

INTRODUCTION

The promotion of smoking cessation is a worldwide Public Health priority. Tobacco addiction represents one of the major risk factors in the development of neoplastic, cardiovascular and respiratory diseases. According to World Health Organization (WHO) data, tobacco smoke kills 5 million people per year worldwide and is responsible for 1 death out of 10 among the adult population. The WHO also estimates that about half of regular smokers are destined to die prematurely, due to tobacco consumption [1], and similar values also emerge from studies conducted on individual Countries [2].

Tobacco consumption increases the risk of cardiovascular (CVD) [3,4] and bronchopulmonary diseases (COPD – chronic obstructive pulmonary disease) [5,6], as well as being the main cause of some types of cancer. It is also a risk factor for several chronic conditions, including type 2 diabetes [7].

The pathological effects of smoking are related to the duration of exposure (number of years) and its intensity (average number of cigarettes per day) [8]. It is estimated that for smokers the risk of developing bronchopulmonary pathologies ranges from 20 to 50%, depending on exposure and intensity, compared to a 10-15% risk – thus limited, although not equal to zero – in non-smokers [6]. In addition, for this disease category, it has been shown that smoking accelerates the progression of the disease [9,10].

Giving up this addiction has beneficial effects on the health of patients. The results of a literature review show that in coronary patients – quitting smoking reduces the risk of mortality by 36% and the risk of infarction by 32% [11].

INTRODUCTION: The promotion of smoking cessation is a worldwide Public Health priority.

OBJECTIVE: To estimate the budget impact on the Italian National Health Service (NHS) of the access to reimbursement of varenicline for the treatment of high risk patients with bronchopulmonary, diabetic and cardiovascular diseases.

METHODS: A closed-group Markov model was developed in order to compare the costs incurred by the NHS to promote smoking cessation with cessation-related savings, using an alternative scenario in which aids to cessation are not reimbursed by the NHS. The analysis was conducted over a 5-year time horizon, in the perspective of the Italian NHS. Efficacy was expressed in terms of smoke abstinence for at least one year, and data was derived from clinical trials; the savings associated with smoking cessation were derived from cost-of-illness studies.

RESULTS: The results show how costs would concentrate in the first year: they are estimated at € 200.6 million, of which € 162.4 million for drug therapy and € 38.2 million for counseling. Average annual savings over the first five years are estimated at € 177.7 million, with a cumulative net impact at 5 years of € -188.0 million (cost-saving). The analysis appears to be robust: sensitivity analyses show that the covering of initial costs occurs in any case between the third and fourth year, and that the treatment remains cost-saving at 5 years.

CONCLUSIONS: The financial impact on the Italian NHS of the reimbursement of varenicline for the treatment of high risk smoking population would be a sustainable healthcare policy, resulting in cost savings starting from the fourth year.

Keywords

Varenicline; Budget Impact; Smoking cessation

© 2017 The Authors. Published by SEEEd srl. This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0)
costs for the damage caused by smoking affected the GDP of the various Countries by 1.04 to 1.39% [12]. In Italy, as in most Western Countries, several tobacco control measures have been introduced in the last decades, both of the educational (e.g. campaigns for the promotion of good lifestyles) and deterring type (e.g. ban on smoking in public places). These policies yielded significant results: according to ISTAT data, from 2001 to 2015 the proportion of smokers dropped from 23.7% to 19.6%, with a significantly higher decrease (from 31% to 24.6%) among men – who started from a very high prevalence – compared to women (from 16.9% to 15.0%).

The prevalence of smokers remains, however, still too high: according to OECD data, Italy is – among the EU15 Countries – sixth in terms of amount of smokers, after Greece, Austria, Spain, France and Germany [13].

In addition to the enhancement of the aforementioned approaches, pharmacological treatments are available to help the smoking cessation.

The aim of this analysis is to estimate the budget impact on the Italian NHS resulting from the access to reimbursement of varenicline for the treatment of patients with COPD, diabetes and CVD.

MATERIALS AND METHODS

Varenicline is a partial agonist of the α4β2 receptors, and exerts a strong antagonistic action against nicotine at the level of the same receptors, as well as a partial agonist action, that occurs with a lower release of dopamine compared to nicotine.

Specifically, by acting nicotine-like at cerebral level, it is able to reduce the desire for cigarettes, thus helping some patients quit smoking.

The model

The model compares the costs incurred to promote smoking cessation and the cessation-related savings, using an alternative scenario in which aids to cessation are not reimbursed by the NHS.

The analysis was conducted over a 5-year time horizon, in the perspective of the Italian NHS. Given the short time horizon considered, savings and costs were not discounted.

The model has a closed-group Markovian structure; in other words, the smokers cohort is considered and followed over time, without considering new entrances in the smoker status (Figure 1).

The Markov model includes the smoker status (naïve, and due to ineffectiveness of the treatment or to relapse) and the non-smoker status. The model does not include the estimate of the mortality rate of smokers since, over the 5-year time horizon adopted, the number of deaths would be extremely low and therefore would not substantially affect the results of the model.

Treatment eligible population

The prevalent Italian population with COPD, diabetes, and CVD – who stated its intention to stop smoking – was considered. This population was offered both a pharmacological support, with varenicline, and a counseling service.

For the estimate of prevalent cases, the data of the National Statistics Institute (ISTAT) – collected during the Statistical Survey on the Health Conditions of the Population and the Resort to Health Services were used [14]. The survey reference period are the 12 months from July 2012 to June 2013.

The sampling design has a general structure that resembles that of the sampling patterns of most household surveys, that is, a multi-stage, district-family design, with stratification of the Districts. In the reference period, the sample involved 60,368 families, for a total number of subjects equal to 119,073.

As for tobacco addiction, the survey was conducted on the population starting from 14 years of age, which in 2013 amounted to 52,352,094 people [15].

People who declare to be suffering from COPD or emphysema are just over 2,225,000, of whom over 544,611 are smokers (Table I). As for diabetes, over 3.4 million people stated to be suffering from it, with a prevalence of 65.1 out of 1,000 inhabitants. Of these, 483,223 are smokers (Table I). Finally, as for CVD, namely AMI (acute myocardial infarction), angina pectoris and stroke, there are a total of 2,682,964 individuals, of whom 333,119 are smokers.
The population eligible for treatment was estimated using the evidence available on the proportion of those who are planning to quit smoking with the help of the drug, net of those who would stop in any case [7]. Patients eligible for pharmacological treatment would therefore be 217,572 with COPD, 154,535 with diabetes and 106,531 with CVD (Table I).

Treatment efficacy

Regarding the efficacy of the treatment (Table II), the values adopted in this analysis are derived from the literature [7]. In particular, efficacy at week 52 of treatment was assumed to be 18.6% for COPD, 20.0% for diabetes and 19.2% for CVD [7]. The meta-analysis carried out by Hoogendoorn et al. [16] showed that the 12-months smoking abstinence rate in patients with COPD who followed the usual care, defined as the absence of any type of smoking cessation intervention, was negligible (about 1%). The rate of relapses was assumed to be 3% per year [7] for the entire eligible population considered.

Costs

The price of the drug used for the calculation is € 339.31, equal to the cost (retail price in class A) of 12 weeks of treatment, as indicated in the SPC [17]: one 0.5 mg tablet once daily for 3 days, then one 0.5 mg tablet twice daily for 4 days and finally one 1.0 mg tablet twice daily for the remaining 11 weeks of treatment (Table III).

As for the counseling service, 4 visits with a psychologist were assumed, for a total amount of € 79.84 (unit cost of the visit equal to € 19.96, as specified by the Italian National Tariff [18]) (Table III).

As for the estimate of the savings resulting from the cessations, this was done separately, for each disease branch1. The average annual cost per COPD patient was assumed to be € 2,723.7 [19]; the estimate for the smoking and non-smoking population was carried out by adopting the savings ratio collected by Sicras-Mainar [6] from a cohort of Spanish patients with COPD specifically treated to promote smoking cessation, which highlighted a cost of € 3,775.4 per smoking patient and € 2,382.4 per no longer smoking patient, with an average annual saving per capita resulting from the cessation of € 1,393.0. Through a similar procedure, patients with diabetes are assumed to have a mean annual cost per patient of € 2,898.0 [20].

Based on the findings of Sicras-Mainar [21] in a cohort of Spanish diabetic patients, a cost of € 3,637.6 and € 2,864.0 is estimated for the smoking and the no longer smoking population, respectively, with an annual saving per cessation of € 774.0.

The annual cost per CVD patient was estimated based on the studies conducted by Fattore et al. [22] on stroke and Roggeri et al. [23] on myocardial infarction and angina, which report values of € 11,747.0 and € 11,464.0, respectively. An average cost was adopted, weighted on the number of the sampled populations analyzed.

Using the findings of Sicras-Mainar [24] in a cohort of Spanish patients with CVD (angina pectoris, AMI, stroke and transient ischemic attack), an average annual cost of € 12,511.0 and € 11,313.5 is estimated, for smokers and ex-smokers, respectively, with an annual saving per cessation of € 1,197.5.

1 Reduction in costs is related to the reduction in the number of visits and days of hospitalization between smoking and no longer smoking patients.

---

<table>
<thead>
<tr>
<th>Input</th>
<th>COPD</th>
<th>Diabetes</th>
<th>CVD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy at week 52 (%)</td>
<td>18.60</td>
<td>20.00</td>
<td>19.20</td>
</tr>
<tr>
<td>Rate of relapses (%)</td>
<td>3.00</td>
<td>3.00</td>
<td>3.00</td>
</tr>
</tbody>
</table>

Table I. Smoker population > 14 years with COPD/emphysema, diabetes, or cardiovascular disease and patients eligible for pharmacological treatment
AMI = acute myocardial infarction; COPD = chronic obstructive pulmonary disease

<table>
<thead>
<tr>
<th>Cost Item</th>
<th>Input</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug cost (€)</td>
<td>339.31</td>
<td>Retail price in class A of 12 weeks of treatment</td>
</tr>
<tr>
<td>Psychological visits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Unit cost (€)</td>
<td>19.96</td>
<td>[18]</td>
</tr>
<tr>
<td>• n.</td>
<td>4.00</td>
<td>Assumption</td>
</tr>
<tr>
<td>• Total cost (€)</td>
<td>79.84</td>
<td>-</td>
</tr>
<tr>
<td>Total cost of therapy (€)</td>
<td>419.15</td>
<td>-</td>
</tr>
</tbody>
</table>

Table II. Treatment efficacy [7]
COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease

<table>
<thead>
<tr>
<th>Cost Item</th>
<th>Input</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD/ emphysema</td>
<td>Diabetes</td>
<td>AMI, angina, stroke</td>
</tr>
<tr>
<td>Total</td>
<td>2,225,039</td>
<td>3,406,477</td>
</tr>
<tr>
<td>Non-smokers</td>
<td>1,680,428</td>
<td>2,923,254</td>
</tr>
<tr>
<td>Smokers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• %</td>
<td>24.48</td>
<td>14.19</td>
</tr>
<tr>
<td>• n.</td>
<td>544,611</td>
<td>483,223</td>
</tr>
<tr>
<td>Smokers willing to quit [7]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• %</td>
<td>39.95</td>
<td>31.98</td>
</tr>
<tr>
<td>• n.</td>
<td>217,572</td>
<td>154,535</td>
</tr>
</tbody>
</table>

Table III. Costs of therapy
Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

First year (of which € 73.8 million for the drug and € 17.4 million for counseling); the cumulative savings in the first five years would amount to € 209.1 million, with a savings of € 117.9 million for the NHS (Figure 2). Treatment of COPD patients becomes cost-saving starting from the third year (Table IV and Figure 2).

Italian diabetic patients who smoke but are also willing to quit are 154,535; should the reimbursability of varenicline be recognized, the cost for the NHS would be € 64.8 million, all concentrated in the first year (of which € 52.4 million for the drug and € 12.3 million for counseling); the cumulative savings achievable in the first five years would amount to € 88.7 million, with a savings of € 23.9 million for the NHS. Treatment of patients with diabetes becomes cost-saving starting from the fourth year (Table V and Figure 3).

Figure 2. Budget impact of varenicline in smokers with COPD

<table>
<thead>
<tr>
<th>Year</th>
<th>Additional costs (€)</th>
<th>Savings (€)</th>
<th>Budget impact (€)</th>
<th>Cumulative budget impact (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>91,195,343</td>
<td>0</td>
<td>91,195,343</td>
<td>91,195,343</td>
</tr>
<tr>
<td>Year 2</td>
<td>-</td>
<td>-54,681,985</td>
<td>-54,681,985</td>
<td>36,513,359</td>
</tr>
<tr>
<td>Year 3</td>
<td>-</td>
<td>-53,041,525</td>
<td>-53,041,525</td>
<td>-16,528,167</td>
</tr>
<tr>
<td>Year 4</td>
<td>-</td>
<td>-51,450,279</td>
<td>-51,450,279</td>
<td>-67,978,446</td>
</tr>
<tr>
<td>Year 5</td>
<td>-</td>
<td>-49,906,771</td>
<td>-49,906,771</td>
<td>-117,885,217</td>
</tr>
</tbody>
</table>

Table IV. Budget impact of varenicline in smokers with COPD

Figure 3. Budget impact of varenicline in smokers with diabetes

Sensitivity analysis

In order to evaluate the impact of the uncertainty of the input parameters on the results obtained, a univariate sensitivity analysis was conducted, in which a variation of relapses of ± 2%, a change in unit savings of ± 10%, and a variation of the population treated of ± 10% were assumed.

RESULTS

Italian COPD patients who smoke but are also willing to quit are 217,572; should the reimbursability of varenicline be recognized for those who are planning to stop smoking with the aid of the drug, net of those who would stop in any case, the cost for the NHS would be € 91.2 million, concentrated in the
first year (of which € 73.8 million for the drug and € 17.4 million for counseling); the cumulative savings in the first five years would amount to € 209.1 million, with a savings of € 117.9 million for the NHS (Figure 2). Treatment of COPD patients becomes cost-saving starting from the third year (Table IV and Figure 2).

Italian diabetic patients who smoke but are also willing to quit are 154,535; should the reimbursability of varenicline be recognized, the cost for the NHS would be € 64.8 million, concentrated in the first year (of which € 52.4 million for the drug and € 12.3 million for counseling); the cumulative savings achievable in the first five years would amount to € 88.7 million, with a savings of € 23.9 million for the NHS. Treatment of patients with diabetes becomes cost-saving starting from the fourth year (Table V and Figure 3).

Italian patients with CVD who smoke but are also willing to quit are 106,531; should the reimbursability of varenicline be recognized, the cost for the NHS would be € 44.6 million, concentrated in the first year (of which € 36.1 million for pharmacotherapy and € 8.5 for counseling); the cumulative savings in the first five years would amount to € 90.8 million, with a saving of € 46.2 million for the NHS. Treatment of patients with CVD becomes cost-saving starting from the third year (Table VI and Figure 4).

**Sensitivity analysis**

The reimbursement of varenicline remains constantly cost-saving starting from the third year of treatment, except where there is a 10% reduction in unit savings or a 10% increase in the population treated: in these cases the treatment becomes however cost-

---

**Table IV. Budget impact of varenicline in smokers with COPD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Additional costs (€)</th>
<th>Savings (€)</th>
<th>Budget impact (€)</th>
<th>Cumulative budget impact (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>64,773,226</td>
<td>0</td>
<td>64,773,226</td>
<td>64,773,226</td>
</tr>
<tr>
<td>Year 2</td>
<td>-</td>
<td>-23,193,097</td>
<td>-23,193,097</td>
<td>41,580,129</td>
</tr>
<tr>
<td>Year 3</td>
<td>-</td>
<td>-22,497,304</td>
<td>-45,680,401</td>
<td>-16,528,167</td>
</tr>
<tr>
<td>Year 4</td>
<td>-</td>
<td>-21,822,385</td>
<td>-67,502,786</td>
<td>-84,030,954</td>
</tr>
<tr>
<td>Year 5</td>
<td>-</td>
<td>-21,167,714</td>
<td>-88,668,299</td>
<td>-117,885,217</td>
</tr>
</tbody>
</table>

**Table V. Budget impact of varenicline in smokers with diabetes**

<table>
<thead>
<tr>
<th>Year</th>
<th>Additional costs (€)</th>
<th>Savings (€)</th>
<th>Budget impact (€)</th>
<th>Cumulative budget impact (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>64,773,226</td>
<td>0</td>
<td>64,773,226</td>
<td>64,773,226</td>
</tr>
<tr>
<td>Year 2</td>
<td>41,580,129</td>
<td>-23,193,097</td>
<td>18,387,032</td>
<td>81,960,129</td>
</tr>
<tr>
<td>Year 3</td>
<td>19,082,824</td>
<td>-22,497,304</td>
<td>-3,414,480</td>
<td>48,545,649</td>
</tr>
<tr>
<td>Year 4</td>
<td>-2,739,561</td>
<td>-21,822,385</td>
<td>-24,561,946</td>
<td>24,083,703</td>
</tr>
<tr>
<td>Year 5</td>
<td>-23,907,275</td>
<td>-21,167,714</td>
<td>-45,074,989</td>
<td>-70,055,192</td>
</tr>
</tbody>
</table>

**Table VI. Budget impact of varenicline in smokers with CVD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Additional costs (€)</th>
<th>Savings (€)</th>
<th>Budget impact (€)</th>
<th>Cumulative budget impact (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>44,652,660</td>
<td>0</td>
<td>44,652,660</td>
<td>44,652,660</td>
</tr>
<tr>
<td>Year 2</td>
<td>41,894,355</td>
<td>-23,758,305</td>
<td>18,136,050</td>
<td>62,800,015</td>
</tr>
<tr>
<td>Year 3</td>
<td>20,505,899</td>
<td>-23,045,555</td>
<td>-2,539,666</td>
<td>39,260,349</td>
</tr>
<tr>
<td>Year 4</td>
<td>-24,505,389</td>
<td>-22,354,189</td>
<td>-46,859,578</td>
<td>-105,153,967</td>
</tr>
<tr>
<td>Year 5</td>
<td>-46,188,952</td>
<td>-21,683,563</td>
<td>-67,872,515</td>
<td>-172,036,522</td>
</tr>
</tbody>
</table>
savings starting from the fourth year. The tornado diagram (Figure 5) reports the five-year savings achieved in the various simulations.

**DISCUSSION**

Studies on the efficacy and cost-effectiveness of the pharmacological smoking cessation therapy, often associated with a motivational support, are relatively recent and show an evolution in terms of achievable goals. The first studies, in fact, were carried out in order to evaluate the effectiveness of the pharmacological treatment: Cahill et al. [25], through a literature review, show the high rate of success (smoking abstinence) in healthy subjects undergoing varenicline therapy, compared with placebo and bupropion. Similarly, other studies [26,27] show a 44% cessation rate after 12 weeks of therapy, versus lower average values (17.6%) for placebo-treated patients.

Efficacy analyses on populations with conditions for which smoking is an aggravating factor were subsequently published: a controlled study [28] – conducted on a sample of 714 smokers with CVD from 15 different countries – evaluated the rate of success of varenicline (administered for 12 weeks) versus placebo, highlighting an average 12-week abstinence rate of 54.1% among the patients treated, versus 18.1% among the controls; the persistence of abstinence at one year remains higher in the varenicline group (19.2%) versus controls (7.2%).

The pharmacoeconomic aspect was examined in depth through an analysis carried out in four European Countries (Belgium, Spain, Portugal and Italy) by Wilson et al. [3]: based on the evidence highlighted by Rigotti et al. [28], the cost per QALY gained with the use of varenicline is estimated at € 6,120 for Belgium, € 5,151 for Spain, € 5,357 for Portugal, and € 5,433 for Italy.

A study with a similar structure to those previously mentioned, conducted in patients with chronic obstructive pulmonary disease (COPD) [29] in Spain, Germany, United Kingdom, Greece and Italy, shows a cost per QALY gained at 52 weeks ranging from a minimum of € 4,478 for UK, up to a maximum of € 10,167 for Italy.

The 10-year extrapolation shows a decrease in the Incremental Cost-Effectiveness Ratio (ICER): in the short term (4-5 years) varenicline is cost-effective adopting a willingness to pay (WTP) greater than € 30,000, while with a longer time horizon it becomes cost-effective with a WTP greater than € 20,000.

A retrospective, multicentre, 24-month study [30] – conducted in a primary care setting in Spain on smokers followed by their GP – considered the varenicline therapy, with or without psychological support, and revealed that psychological support increases the adherence to therapy, and therefore the success in quitting smoking.

Various studies have shown that, increasing the adherence to treatment, the public funding of antismoking drugs may be an essential condition for the effectiveness of the treatment itself [31,32].

The Budget Impact deriving from the access to reimbursement of smoking cessation drugs, and in particular varenicline, was repeatedly analyzed: Taylor et al. [33] demonstrated the economic benefits deriving from the reimbursement of varenicline in the perspective of the UK NHS; in Spain Jiménez-Ruiz et al. [5] came to the same conclusions for COPD patients over a 5-year time horizon.

Cedillo et al. [7] – considering as target population smokers with COPD, t2-DM or CVD, who represent a high-risk population both in terms of health and healthcare resources – estimate that varenicline reimbursement would be cost-saving from the third year.

This study, adopting a perspective similar to that of Cedillo et al. [7], evaluates the budget impacts of the access to reimbursement of varenicline, in the perspective of the Italian NHS.

Overall, a burden of € 200.6 million is estimated for the first year – of which € 162.4 million for drug therapy and € 38.2 million for counseling – which would be offset in the third year; from the fourth year, the treatment is cost-saving, with a 5-year savings of € 188.0 million.

It was assumed that all eligible patients were treated in the first year, which is an apparently unlikely supposition, because the burdens will certainly be divided over several years: for the purposes of the budget impact assessment, it was decided to provide the most extreme data, avoiding the introduction of arbitrary hypotheses on the uptake of patients. Based on the aforementioned assumptions and data, the financial impact (all concentrat-
ed in the first year) is less than 1.85% of the Class A public pharmaceutical expenditure [34], and less than 0.002% of the national public health expenditure, without even considering any wholesale discounts.

CONCLUSIONS

The financial impact on the Italian NHS of the reimbursement of varenicline for the high-risk smoking population willing to stop would be a sustainable healthcare policy, resulting cost-savings from the fourth year. In particular, it should be noted that the costs, that was estimated at € 200.6 million, would be concentrated in the first year. Average annual savings over the first five years are estimated at € 77.7 million, with a five-year savings of € 188.0 million. Conclusions appear to be robust: sensitivity analyses show that the covering of initial costs occurs in any case between the third and fourth year, and that the treatment remains in any case cost-saving at 5 years. The perspective used is that of the Italian NHS, and therefore it does not take into account the indirect costs (benefits for society deriving from lower productivity losses) and the out-of-pocket direct costs incurred by families: the analysis can therefore be considered conservative.

Conflict of interests

FS reports financial relationships with 3M, Abbott, Bayer, Biogen Idec, Biomarine, BMS, Boehringer-Ingelheim, Celgene, Daiichi Sankyo, Edwards, Eli Lilly, Genzyme, GlaxoSmithKline, Janssen Cilag, Johnson & Johnson, Lundbeck, Medac, MSD Italia, Medtronic, Nestle Health Science, Novartis, Novo Nordisk, OBI, Otsuka, Pfizer, Roche, Sanofi, Sanofi Pasteur MSD, Servier, Sigma Tau, Stroder, Teva, outside the present work.

BP reports financial relationships with Abbott, Bayer, Daiichi Sankyo, Edwards, Eli Lilly, Genzyme, Lundbeck, Medac, Otsuka, Pfizer, Roche, Servier, outside the present work.

RLM has nothing to disclose.

BIBLIOGRAFIA

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

15. ISTAT – Aspects of daily life. Year 2013. Available at https://www.istat.it/it/archivio/129916
34. Medicines use in Italy – Osmed Report 2015. Available at http://www.aifa.gov.it/content/osmed-report